Boehringer Ingelheim reported phase 3 results for survodutide, a dual-acting obesity shot licensed from Zealand Pharma. In the Synchronize-1 trial, the company said participants on survodutide lost significantly more weight than placebo over 76 weeks, with continued analyses also assessing muscle and body composition. Boehringer described weight loss up to 17% among those who stayed on treatment and a high proportion achieving clinically meaningful weight loss thresholds. The readout adds to the competitive landscape of non-Lilly/non-Novo obesity programs that combine GLP-1-related signaling with additional pathways. Analysts are expected to look closely at side-effect profiles and longer follow-up, including disease-area studies such as MASH, before fully benchmarking against established leaders.